Quest Diagnostics expands AD-Detect with Roche pTau217 and ABeta panel
Aug 24, 2026, 7:27 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The addition of FDA-cleared pTau217 from Roche and a new multi-biomarker AD-Detect panel expands Quest’s TAM in Alzheimer's testing, potentially boosting hospital/clinic lab volumes and AD-Detect-related revenue. While the direct impact on DGX earnings is not immediate, the broader AD-Detect ecosystem growth could lift demand for Quest’s lab services and related instrumentation over the 2026–2027 period, similar to prior biomarker test rollouts which have catalyzed testing volumes for major labs.
AI summary
What happened, with direct paths to the underlying reporting
Quest Diagnostics announced two AD-Detect updates, adding Roche’s FDA-cleared pTau217 and launching a multi-biomarker ABeta42/40, p-tau217, ApoE panel. The moves broaden access to blood-based Alzheimer’s testing and could lift Quest’s AD-Detect revenue in 2026–27 as it expands coverage to roughly 2,000 locations and advances panel integration.
Quest Diagnostics to add Roche pTau217 to AD-Detect; FDA-cleared.
Roche pTau217 enables rule-in/out across care settings; Quest launch planned.
Quest operates ~2,000 U.S. locations for testing.
Multi-biomarker approach could improve Alzheimer's pathology detection versus single biomarker tests.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Quest Diagnostics delivered a solid Q2 with adjusted EPS of $3.12 and revenue of $3.043 billion, up 10.2% year over year and 10% organically. Broad demand across physician, hospit…
Quest Diagnostics reported a strong Q2 with revenues of about $3.04B and organic growth of 10%, prompting a lift in full-year 2026 guidance to $11.95–$12.05B and higher EPS ranges…
Quest Diagnostics has raised its profit and revenue forecasts for 2026, following first-quarter results that exceeded Wall Street estimates. The company cited resilient demand for…
Quest Diagnostics projected its 2026 profit and revenue to exceed Wall Street expectations, driven by robust demand for diagnostic tests, following a strong performance in Q4. Thi…
